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Objectives: To test the activity of tigecycline combined with 16 antimicrobials in vitro against 22
Gram-positive and 55 Gram-negative clinical isolates.
Methods: Antibiotic interactions were determined by chequerboard and time–kill methods.
Results: By chequerboard, of 891 organism–drug interactions tested, 97 (11%) were synergistic, 793
(89%) were indifferent and 1 (0.1%) was antagonistic. Among Gram-positive pathogens, most syner-
gisms occurred against Enterococcus spp. (7/11 isolates) with the tigecycline/rifampicin combination.
No antagonism was detected. Among Gram-negative organisms, synergism was observed mainly with
trimethoprim/sulfamethoxazole against Serratia marcescens (5/5 isolates), Proteus spp. (2/5) and
Stenotrophomonas maltophilia (2/5), with aztreonam against S. maltophilia (3/5), with cefepime
and imipenem against Enterobacter cloacae (3/5), with ceftazidime against Morganella morganii (3/5),
and with ceftriaxone against Klebsiella pneumoniae (3/5). The only case of antagonism occurred
against one S. marcescens with the tigecycline/imipenem combination. Selected time–kill assays con-
firmed the bacteriostatic interactions observed by the chequerboard method. Moreover, they revealed a
bactericidal synergism of tigecycline with piperacillin/tazobactam against one penicillin-resistant
Streptococcus pneumoniae and with amikacin against Proteus vulgaris.
Conclusions: Combinations of tigecycline with other antimicrobials produce primarily an indifferent
response. Specific synergisms, especially against enterococci and problematic Gram-negative isolates,
might be worth investigating in in vitro models and/or in animal models simulating the human
environment.
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Introduction
Tigecycline is the first glycylcycline antibiotic available for
clinical use.1 Tigecycline is highly active in vitro against
most common Gram-positive and Gram-negative pathogens,
including methicillin-resistant Staphylococcus aureus (MRSA),
glycopeptide-intermediate S. aureus (GISA), penicillin-resistant
Streptococcus pneumoniae, vancomycin-resistant enterococci
and extended-spectrum b-lactamase-producing Escherichia coli
and Klebsiella pneumoniae.1–3 The activity of tigecycline is not
affected by common tetracycline resistance mechanisms, includ-
ing tetracycline-specific efflux pumps and ribosomal protection.
Nevertheless, some isolates tend to have decreased susceptibility
to tigecycline (Proteus mirabilis, indole-positive Proteus spp.,
Morganella morganii, Providencia spp. and a few strains of
Serratia marcescens and K. pneumoniae) or demonstrate resist-
ance (Pseudomonas aeruginosa).2,3 These strains have constitu-
tively overexpressed multidrug efflux pump systems for which
tigecycline is a substrate, such as AcrAB in P. mirabilis, M.
morganii and K. pneumoniae4–6 and MexXY in P. aeruginosa.7
The present study investigated the effect of combining tige-
cycline with other antibacterials against representative clinical
isolates of Gram-positive and Gram-negative organisms.
Materials and methods
Microorganisms
A total of 77 bacterial isolates (22 Gram-positive and 55 Gram-
negative) were tested (Table 1). These isolates were recovered
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Corresponding author. Tel: þ41-21-692-5612; Fax: þ41-21-692-5605; E-mail: jose.entenza@unil.ch
Journal of Antimicrobial Chemotherapy (2008) 61, 371–374
doi:10.1093/jac/dkm459
Advance Access publication 22 November 2007
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
371
# The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
from human infections (one isolate per patient). Gram-positive
isolates included six Enterococcus faecalis [five vancomycin-
susceptible and one vancomycin-resistant (VanA type)], five
Enterococcus faecium [four vancomycin-susceptible and one
vancomycin-resistant (VanA type)], six S. aureus (two methicil-
lin-susceptible S. aureus, three MRSA and one GISA) and five
S. pneumoniae (three penicillin-susceptible and two penicillin-
resistant). Gram-negative isolates were chosen at random to rep-
resent a spectrum of bacteria and resistance phenotypes encoun-
tered in clinical practice, e.g. b-lactam-resistant, quinolone-
resistant and/or trimethoprim/sulfamethoxazole-resistant strains,
and included five isolates of each of the following species:
Acinetobacter spp., Citrobacter freundii, Enterobacter cloacae,
Enterobacter aerogenes, E. coli, K. pneumoniae, M. morganii,
Proteus spp., P. aeruginosa, S. marcescens and
Stenotrophomonas maltophilia.
Antimicrobial agents
The antibiotics tested in combination with tigecycline are shown
in Table 1. Tigecycline was provided by Wyeth Research (Pearl
River, NY, USA). All the other drugs were commercially avail-
able products.
MIC determination
MICs were determined using the broth microdilution method in
Mueller–Hinton broth (MHB). S. aureus ATCC 29213, E. fae-
calis ATCC 29212, E. coli ATCC 25922, K. pneumoniae ATCC
27736 and P. aeruginosa ATCC 27853 were used as quality
control strains. Interpretative criteria for tigecycline MICs were
defined on the basis of the United States Food and Drug
Administration susceptibility breakpoints of 0.25 mg/L for
streptococci and enterococci and 0.5 mg/L for S. aureus, and
2 mg/L for susceptibility, 4 mg/L for intermediate and 8 mg/
L for resistance when testing Gram-negative organisms.1,3
Chequerboard studies
Antibiotic interactions were assessed by the chequerboard method
in 96-well microtitre plates. The wells were inoculated with
105 cfu/mL, and the plates were incubated for 24 h at 358C.
Fractional inhibitory concentrations (FICs) were calculated as the
MIC of drug A or B in combination/the MIC of drug A or B
alone, and the FIC index (FICI) was obtained by adding the FIC
values. FICIs of 0.5 were interpreted as synergistic, those of
.0.5 but 4 were considered as indifferent, and those of .4
were interpreted as antagonistic.8,9
Time–kill assays
In selected cases, synergism and antagonism were also tested in
time–kill experiments. Flasks containing MHB were inoculated
with 106 cfu/mL of the test organism. For synergism, antibiotics
were added to the flasks at concentrations equivalent to 0.25
the MIC for the specific isolate. For testing the agreement with
the only case of antagonism observed by the chequerboard
results (tigecycline in combination with imipenem, each drug
was tested alone at the following concentrations): tigecycline
0.25 and 2 the MIC, imipenem 0.032 and 2 the MIC;
and in combination at the following concentrations: tigecycline
0.25 the MIC plus imipenem 2 the MIC, and tigecycline
2 the MIC plus imipenem 0.032 the MIC, i.e. the highest
drug combinations showing turbidity in microtitre plates.
Table 1. Results of chequerboard testing of tigecycline and a second antibacterial agent against Gram-positive and Gram-negative bacteria
No. of strains showing synergy/total no. of strains
AMC TZP CRO CAZ FEP IPM MEM ATM AMK SXT CIP MXF RIF VAN TEC LZD
Gram-positive
E. faecalis 1/6 0/6 1/6 ND 1/6 ND 1/6 ND 1/6 0/6 0/6 0/6 4/6 0/6 1/6 0/6
E. faecium 1/5 0/5 0/5 ND 0/5 ND 0/5 ND 0/5 0/5 0/5 0/5 3/5 0/5 0/5 1/5
S. aureus 2/6 0/6 1/6 ND 0/6 ND 0/6 ND 0/6 0/6 0/6 0/6 0/6 0/6 0/6 1/6
S. pneumoniae 1/5 1/5 0/5 ND 0/5 ND 0/5 ND 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
total 5/22 1/22 2/22 1/22 1/22 1/22 0/22 0/22 0/22 7/22 0/22 1/22 2/22
Gram-negative
Acinetobacter spp. 0/5 0/5 0/5 0/5 1/5 0/5 0/5 0/5 1/5 0/5 0/5 ND ND ND ND ND
C. freundii 0/5 0/5 1/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 ND ND ND ND ND
E. aerogenes 0/5 0/5 0/5 0/5 0/5 1/5 0/5 1/5 2/5 0/5 0/5 ND ND ND ND ND
E. cloacae 0/5 1/5 2/5 2/5 3/5 3/5 1/5 2/5 2/5 1/5 0/5 ND ND ND ND ND
E. coli 0/5 0/5 0/5 1/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5 ND ND ND ND ND
K. pneumoniae 0/5 0/5 3/5 2/5 0/5 0/5 0/5 0/5 2/5 0/5 0/5 ND ND ND ND ND
M. morganii 0/5 2/5 2/5 3/5 0/5 0/5 0/5 0/5 0/5 1/5 0/5 ND ND ND ND ND
Proteus spp. 0/5 1/5 1/5 0/5 0/5 0/5 0/5 1/5 2/5 2/5 0/5 ND ND ND ND ND
P. aeruginosa 0/5 0/5 1/5 1/5 0/5 1/5 0/5 0/5 0/5 0/5 1/5 ND ND ND ND ND
S. marcescens 1/5 2/5 0/5 0/5 1/5 0/5 0/5 1/5 1/5 5/5 0/5 ND ND ND ND ND
S. maltophilia 0/5 0/5 0/5 2/5 2/5 0/5 1/5 3/5 2/5 2/5 0/5 ND ND ND ND ND
total 1/55 6/55 10/55 12/55 8/55 5/55 2/55 8/55 12/55 11/55 1/55
AMC, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem;
ATM, aztreonam; AMK, amikacin; SXT, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; MXF, moxifloxacin; RIF, rifampicin; VAN, vancomycin; TEC,
teicoplanin; LZD, linezolid; ND, not done.
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Synergism, indifference and antagonism were defined as
described previously.8 Each time–kill experiment was repeated
two times independently.
Results
Susceptibility results
Tigecycline was active (MIC 0.01–0.5 mg/L) against all of the
22 Gram-positive isolates tested regardless of their resistance
pattern to other drugs. For the 55 Gram-negative test organisms,
tigecycline was active (MIC  2 mg/L) against 46 (84%),
borderline against 4 (7%; 3 Proteus spp. and 1 M. morganii),
and ineffective (MIC  8 mg/L) against 5 (9%; all being
P. aeruginosa) isolates.
FICIs—Gram-positive isolates
Over the 286 individual antibiotic and bacteria combinations
with the Gram-positive isolates (Table 1), synergism (FICI
0.5) occurred in 21 of 286 (7%) cases and indifference (FICI
.0.5 but 4) in 265 of 286 (93%) cases, irrespective of the
drug resistance pattern to other drugs. No antagonism (FICI .4)
was detected. High rates of synergism occurred against
Enterococcus spp. (synergism in 7 of 11 isolates) when tigecy-
cline was combined with rifampicin. The combination of tigecy-
cline with amoxicillin/clavulanate was also synergistic against
two (both MRSA) of the six S. aureus isolates.
FICIs—Gram-negative isolates
Over the 605 individual antibiotic and bacteria combinations
with the Gram-negative isolates (Table 1), synergism occurred
in 76 of 605 (13%) cases and indifference in 528 of 605 (87%)
cases. Synergism was observed mainly with trimethoprim/
sulfamethoxazole against S. marcescens (five of five isolates),
Proteus spp. (two of five) and S. maltophilia (two of five); with
cefepime and imipenem against E. cloacae (three of five); with
ceftazidime against M. morganii (three of five); with ceftriaxone
against K. pneumoniae (three of five); and with aztreonam
against S. maltophilia (three of five isolates). Other synergisms
occurred in various isolates with various antibiotic combi-
nations, including with amikacin against a total of 12 of the 55
organisms. Antagonism occurred only in one case (0.2% of the
tests) with imipenem against an S. marcescens isolate.
Time–kill assays
In selected cases (three Gram-positive isolates and nine Gram-
negative isolates), synergism or antagonism was further tested in
time–kill experiments [see Figures S1 and S2, available as
Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
For Gram-positive bacteria, time–kill experiments confirmed
that tigecycline plus rifampicin against enterococci was more
active than either drug alone. In addition, they revealed a bac-
tericidal synergism between tigecycline and piperacillin/tazobac-
tam against one penicillin-resistant pneumococcal isolate.
Time–kill experiments with Gram-negative isolates confirmed
the bacteriostatic synergism between tigecycline and imipenem
against E. cloacae 1085, tigecycline and ceftazidime against M.
morganii 48, tigecycline and trimethoprim/sulfamethoxazole
against P. mirabilis 119 and S. marcescens 220, tigecycline and
amikacin against S. maltophilia 58 and P. mirabilis 35, and
tigecycline and aztreonam against S. maltophilia 59. In addition,
bactericidal synergism was observed between tigecycline and
amikacin against Proteus vulgaris 60.
We also tested the only case of antagonism revealed by the
chequerboard method against one isolate of S. marcescens.
When 0.25 MIC of tigecycline was mixed with increasing
concentrations of imipenem, the MIC of imipenem reproducibly
increased by 4. However, this antagonism was limited to this
sub-MIC concentration and did not occur at greater concen-
trations of tigecycline. Likewise, when 0.032 MIC of imipe-
nem was added to increasing concentrations of tigecycline, the
MIC of tigecycline consistently increased by 4. When we
tested tigecycline in combination with imipenem by time–kill
assays at the highest drug combinations showing turbidity in
microplates, the antagonism was confirmed when tigecycline at
0.25 the MIC was combined with imipenem at 2 the MIC.
However, antagonism was not detected when tigecycline at 2
the MIC was combined with imipenem at 0.032 the MIC.
The results of time–kill assays agreed reasonably well with
the chequerboard method: for the 34 combinations examined
with both methods, synergy results by chequerboard were con-
firmed by time–kill studies in 10/20 (50%) occasions, indiffer-
ence in 11/13 (85%) and antagonism in 1/1 (100%).
Discussion
The present results indicate that the interaction of tigecycline
with other drugs against Gram-positive and Gram-negative bac-
teria was essentially indifferent. Thus, tigecycline could be used
safely with other antibacterial compounds, for instance, in
empirical antibiotherapy requiring a very broad-spectrum anti-
biotic coverage or in intra-abdominal polymicrobial infection
involving a possible tigecycline-resistant Pseudomonas. An
antagonism was observed in only one single case (0.1% of
cases), with tigecycline in combination with imipenem. This
antagonism was limited to a very sub-MIC concentration of tige-
cycline (0.25 the MIC). A speculative explanation for this
observation is that sub-MIC concentrations of either of the drugs
could induce drug efflux of the partner compound. As the
phenomenon occurred in a restricted window of sub-MIC con-
centrations, its potential clinical relevance is unclear.
The fact that drug interactions between tigecycline and other
compounds were essentially indifferent supports previous results
using the chequerboard method.10 However, the present exper-
iments also revealed a number of interesting synergisms. These
synergisms were of either of two types, i.e. (i) bacteriostatic, as
observable by chequerboard and time–kill assays, and/or (ii) bac-
tericidal, as revealed only by time–kill assays. Two of the syner-
gisms revealed by the chequerboard method tended to be both
drug-class and organism dependent, including tigecycline and
rifampicin against Enterococcus spp. and tigecycline and tri-
methoprim/sulfamethoxazole against E. cloacae, Proteus spp. and
S. maltophilia. Both synergisms could be of clinical relevance, as
the organisms they target belong to potentially problematic multi-
resistant species. The generalization of these synergisms to
additional isolates of these species and their possible relevance in
infection models might be worth testing. Other synergisms were
Tigecycline in combination with other antibacterials
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non-specifically spread over several drugs and organisms and
might be more difficult to interpret. Eventually, time–kill assays
disclosed a clear bactericidal synergism between tigecycline and
b-lactams against one tested S. pneumoniae and tigecycline and
amikacin against one tested P. vulgaris. Although these prelimi-
nary observations need to be investigated further, they might open
new perspectives for the utilization of tigecycline with other anti-
bacterials in specific types of infections.
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